Duloxetine in the treatment of major depressive disorder: Comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients

Journal of Clinical Psychiatry

Volumn 67, Issue 9, 2006, Pages 1379-1390

  Lewis Fernández, Roberto ^a,c   Blanco, Carlos ^a   Mallinckrodt, Craig H ^b   Wohlreich, Madelaine M ^b   Watkin, John G ^b   Plewes, John M ^b  

^a New York State Psychiatric Institute ^*  (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAL HYDRATE; DULOXETINE; PLACEBO; ZOLPIDEM;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CAUCASIAN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HISPANIC; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PULSE RATE; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VITAL SIGN; WEIGHT CHANGE; XEROSTOMIA;

EID: 33750074145     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0908     Document Type: Article

References (53)

1. Current Population Survey (CPS). US Bureau of Census (PCP-5). Washington, DC: Government Printing Office; 2002
2. Robins L, Regier DA. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51: 8-19
4. Burnam MA, Hough RL, Karno M, et al. Acculturation and lifetime prevalence of psychiatric disorders among Mexican Americans in Los Angeles. J Health Soc Behav 1987;28:89-102
5. Grant BF, Stinson FS, Hasin DS, et al. Immigration and lifetime prevalence of DSM-IV psychiatric disorders among Mexican Americans and non-Hispanic whites in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:1226-1233
6. Ortega AN, Rosenheck R, Alegria M, et al. Acculturation and the lifetime risk of psychiatric and substance use disorders among Hispanics. J Nerv Ment Dis 2000;188:728-735
7. Vega WA, Kolody B, Aguilar-Gaxiola S, et al. Lifetime prevalence of DSM-III-R psychiatric disorders among urban and rural Mexican Americans in California. Arch Gen Psychiatry 1998;55:771-778
8. Alderete E, Vega WA, Kolody B, et al. Effects of time in the United States and Indian ethnicity on DSM-III-R psychiatric disorders among Mexican Americans in California. J Nerv Ment Dis 2000;188:90-100
9. Vega WA, Sribney WM, Aguilar-Gaxiola S, et al. 12-month prevalence of DSM-III-R psychiatric disorders among Mexican Americans: nativity, social assimilation, and age determinants. J Nerv Ment Dis 2004;192: 532-541
10. Vega WA, Sribney WM. The demography of depression in the Latino population. In: Aguilar-Gaxiola SA, Gullota T, Magaña CG, eds. Prevention and Treatment of Depression in Latinos. New York, NY: Springer. In press
11. Malgady RG, Rogler LH, Costantino G. Ethnocultural and linguistic bias in mental health evaluation of Hispanics. Am Psychol 1987;42:228-234
12. Price CS, Cuéllar I. Effects of language and related variables on the expression of psychopathology in Mexican-American psychiatric patients. Hispanic J Behav Sci 1981;3:145-160
13. Skaer TL, Sclar DA, Robison LM, et al. Trends in the rate of depressive illness and use of antidepressant pharmacotherapy by ethnicity/race: an assessment of office-based visits in the United States, 1992-1997. Clin Ther 2000;22:1575-1589
14. Sleath BL, Rubin RH, Huston SA. Antidepressant prescribing to Hispanic and non-Hispanic white patients in primary care. Ann Pharmacother 2001;35:419-423
15. Borowsky SJ, Rubenstein LV, Meredith LS, et al. Who is at risk of nondetection of mental health problems in primary care? J Gen Intern Med 2000;15:381-388
16. Miranda J, Cooper LA. Disparities in care for depression among primary care patients. J Gen Intern Med 2004;19:120-126
17. Miranda J, Duan N, Sherbourne C, et al. Improving care for minorities: can quality improvement interventions improve care and outcomes for depressed minorities? results of a randomized, controlled trial. Health Serv Res 2003;38:613-630
18. Sclar DA, Robison LM, Skaer TL, et al. Ethnicity and the prescribing of antidepressant pharmacotherapy: 1992-1995. Harv Rev Psychiatry 1999;7:29-36
19. Young AS, Klap R, Sherbourne CD, et al. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001;58:55-61
20. Lin KM. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry 2001;62(suppl 13):13-19
21. Mendoza R, Smith MW. The Hispanic Response to Psychotropic Medications. In: Ruiz P, ed. Ethnicity and Psychopharmacology. Washington, DC: American Psychiatric Press; 2000:55-82
22. Marcos LR, Cancro R. Pharmacotherapy of Hispanic depressed patients: clinical observations. Am J Psychother 1982;36:505-512
23. Escobar JI, Tuason VB. Antidepressant agents: a cross-cultural study. Psychopharmacol Bull 1980;16:49-52
24. Wagner GJ, Maguen S, Rabkin JG. Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients. Psychiatr Serv 1998;49:239-240
25. Sánchez-Lacay JA, Lewis-Fernández R, Goetz D, et al. Open trial of nefazodone among Hispanics with major depression: efficacy, tolerability, and adherence issues. Depress Anxiety 2001;13:118-124
26. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36: 106-132
27. Delgado PL, Mallinckrodt CH, Brunner E, et al. Duloxetine for the long-term treatment of major depressive disorder in Hispanic patients from Mexico. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif
28. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-231
29. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399
30. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315
31. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
32. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53
33. Eli Lilly and Company. Duloxetine versus placebo in the treatment of major depression. Available at: http://www.lillytrials.com/results_files/ cymbalta/cymbalta_summary_3327b.pdf. Accessibility verified Aug 25, 2006
34. Eli Lilly and Company. Duloxetine versus placebo and paroxetine in the acute treatment of major depression, study group A. Available at: http://www.lillytrials.com/results_files/cymbalta/cymbalta_summary_4091a. pdf. Accessibility verified Aug 25, 2006
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
36. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
37. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
38. DeLoach LJ, Higgins MS, Caplan AB, et al. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102-106
39. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992;22:307-319
40. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res 1993;27: 259-273
41. Faries D, Herrera J, Rayamajhi J, et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000;34:3-10
42. Cleary M, Guy W. Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1975;1:115-120
43. Maier W, Philipp M. Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale. Pharmacopsychiatry 1985;18:114-115
44. Mallinckrodt CH, Sanger TM, Dube S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003;53:754-760
45. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004;61:310-317
46. Littell RC, Milliken GA, Stroup WW, et al. SAS System for Mixed Models. Cary, NC: SAS Institute Inc.; 1996
47. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985;41:361-372
48. Stahl SM. Why settle for silver, when you can go for gold? response vs. recovery as the goal of antidepressant therapy. J Clin Psychiatry 1999;60:213-214
49. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25: 1171-1180
50. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992;149:1046-1052
51. Alonso M, Val E, Rapaport MH. An open-label study of SSRI treatment in depressed Hispanic and non-Hispanic women. J Clin Psychiatry 1997; 58:31
52. Currier MB, Molina G, Kato M. Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients: a prospective study. Psychosomatics 2004;45:210-216
53. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003;64: 1237-1244